Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-295P is a pseudogene related to the small nuclear RNA U6, a core RNA in the spliceosome responsible for excising introns from pre-mRNA in eukaryotic nuclei[1][3]. Unlike functional U6 snRNA, RNU6-295P is considered a non-functional genomic remnant and does not encode a functional RNA or protein, nor does it participate directly in splicing or other biochemical pathways[1][2][4]. U6 snRNA pseudogenes are prevalent in vertebrate genomes as evolutionary by-products, and although some pseudogenes may have roles as regulatory RNAs or chromatin elements, there is no evidence that RNU6-295P has such functions, nor is it used as a drug target or biomarker[2][4]. The target RNU6-295P is not a therapeutically actionable target, and its inclusion as a drug target, receptor, enzyme, or biomarker is incorrect; it is a pseudogene without established biological or clinical relevance[1][3][4].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 295, pseudogene (RNU6-295P).